OTC Firms Should Improve Monograph Compliance, Registration – CDER
This article was originally published in The Tan Sheet
CDER recommends the OTC industry ensure product innovations comply with monographs or have FDA approval prior to marketing. Umbrella-branding and facility registration rank high for the drug center in 2013.
You may also be interested in...
The latest regulatory agenda says FDA targets issuing proposed rules on OTC antimicrobial hand wash products in February and leave-on antiseptics in July, and in February to finalize an OTC monograph for oral bronchodilator in combination with expectorants or oral nasal decongestants.
Many monograph OTCs are overshadowed in the marketplace by NDA products and have much less space on store shelves. With some NDA-approved ingredients moved to monographs, FDA pre-market approval would no longer be required and more firms could make those products.
Critics of drug labels' effectiveness say reducing errors in the use of OTC drugs depends largely on a change manufacturers oppose - reining in umbrella branding